Abstract
We present the case of a patient with a double transformation during the evolution of chronic hematopoietic malignancy - JAK2 positive chronic myeloproliferative neoplasm; the first transformation had occurred previous to the presentation in our Department, but the second transformation was observed in evolution and it was into a rapidly evolving disease, followed by survival of less than one month. We underline the very poor prognosis -- overall survival of 2.5 years from initial presentation -- a much reduced survival for a chronic myeloproliferative neoplasm, probably due also to multiple associated pathology. Also, the other interesting element of the case is related to the dysfunctional platelets -- hemorrhagic complication at increased platelet count, respectively thrombosis at platelet count under 20000/mmc.
MeSH terms
-
Aged, 80 and over
-
Antineoplastic Agents / therapeutic use
-
Biomarkers / blood
-
Cell Transformation, Neoplastic*
-
Chronic Disease
-
Fatal Outcome
-
Humans
-
Janus Kinase 2 / genetics
-
Leukemia, Myeloid, Acute / diagnosis*
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / enzymology
-
Leukemia, Myeloid, Acute / genetics
-
Male
-
Mutation
-
Platelet Count
-
Polycythemia Vera / diagnosis*
-
Polycythemia Vera / drug therapy
-
Polycythemia Vera / enzymology
-
Polycythemia Vera / genetics
-
Primary Myelofibrosis / diagnosis*
-
Primary Myelofibrosis / drug therapy
-
Primary Myelofibrosis / enzymology
-
Primary Myelofibrosis / genetics
-
Prognosis
-
Pulmonary Embolism / diagnosis
-
Risk Factors
-
Splenomegaly
-
Thrombocytosis / diagnosis
-
Venous Thromboembolism / diagnosis
Substances
-
Antineoplastic Agents
-
Biomarkers
-
JAK2 protein, human
-
Janus Kinase 2